Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 15/20 | 0.48 |
| ▸ | ALOX5 | P09917 | 13/20 | 0.48 |
| ▸ | PPARG | P37231 | 12/20 | 0.46 |
| ▸ | PTGES | O14684 | 7/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3217432 | 0.84 | PSEN1 (0.48) | PSEN1ALOX5PPARGPTGES | |
| SCHEMBL3212790 | 0.81 | CNR1 (0.44) | CNR1CNR2 | |
| SCHEMBL3212785 | 0.80 | CNR1 (0.43) | CNR1CNR2 | |
| SCHEMBL3212794 | 0.80 | CNR1 (0.43) | CNR1CNR2 | |
| SCHEMBL2767996 | 0.80 | CNR1 (0.48) | PPARGCNR1CNR2 | |
| SCHEMBL2767992 | 0.80 | CNR1 (0.48) | PPARGCNR1CNR2 | |
| SCHEMBL3843524 | 0.79 | CNR1 (0.47) | CNR1CNR2 | |
| SCHEMBL3843523 | 0.79 | CNR1 (0.47) | CNR1CNR2 | |
| SCHEMBL2767358 | 0.72 | CNR2 (0.56) | CNR1CNR2 | |
| SCHEMBL15770011 | 0.70 | FFAR1 (0.49) | PSEN1ALOX5PPARGPTGES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100048544-A1 | PYRROLO (3, 2, 1-IJ) QUINOLINE-4-ONE-DERIVATIVES FOR TREATING TUBERCULOSIS | GLAXO GROUP LIMITED (GB) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048544-A1 | PYRROLO (3, 2, 1-IJ) QUINOLINE-4-ONE-DERIVATIVES FOR TREATING TUBERCULOSIS | NQO2, MT-ND1, SDHB | PSEN1 3439/4885ALOX5 1072/4885PPARG 199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.